TY - JOUR
TI - mRNA expression of specific HER ligands and their association with
clinical outcome in patients with metastatic breast cancer treated with
trastuzumab
AU - Rapti, Vassiliki
AU - Moirogiorgou, Evangelia
AU - Koliou,
AU - Georgia-Angeliki
AU - Papadopoulou, Kyriaki
AU - Binas, Ioannis and
AU - Pentheroudakis, George
AU - Bafaloukos, Dimitrios
AU - Bobos, Mattheos and
AU - Chatzopoulos, Kyriakos
AU - Chrisafi, Sofia
AU - Christodoulou, Christos
AU - and Nicolaou, Irene
AU - Sotiropoulou, Maria
AU - Magkou, Christina and
AU - Koutras, Angelos
AU - Papakostas, Pavlos
AU - Kotsakis, Athanasios and
AU - Razis, Evangelia
AU - Psyrri, Amanda
AU - Tryfonopoulos, Dimitrios and
AU - Pectasides, Dimitrios
AU - Res, Eleni
AU - Alexopoulos, Athanasios and
AU - Kotoula, Vassiliki
AU - Fountzilas, George
JO - Oncology Letters
PY - 2022
VL - 23
TODO - 1
SP - null
PB - SPANDIDOS PUBL LTD
SN - 1792-1074, 1792-1082
TODO - 10.3892/ol.2021.13141
TODO - metastatic breast cancer; trastuzumab; biomarkers; HER2; HER ligands
TODO - Prognostic and predictive biomarkers are being studied for the diagnosis
and treatment of breast cancer. The present study retrospectively
assessed the mRNA expression of HER family receptor ligands and of other
potential prognostic biomarkers and their association with time to
progression (TTP), survival and clinicopathological characteristics in
patients with metastatic breast cancer (MBC) treated with trastuzumab. A
total of 145 tumour tissue samples were analysed. mRNA expression
analysis of the transcripts of interest was performed and the
association of these markers with selected clinicopathological
parameters was examined. HER2 status was centrally re-evaluated. Only
67.6% of patients were truly HER2-positive according to the central
HER2 re-evaluation. Heparin binding epidermal growth factor (EGF)-like
growth factor, transforming growth factor beta 1 (TGFB1) and thyroid
hormone receptor alpha (THRA) mRNA expression was higher in
HER2-positive patients (P=0.026, P<0.001 and P<0.001). Insulin-like
growth factor binding protein 4 was correlated with retinoic acid
receptor alpha, TGFB1 and THRA (rho=0.45, rho=0.60 and rho=0.45). In
HER2-positive patients, high neuregulin 1 and high betacellulin were
unfavourable factors for TTP [hazard ratio (HR) = 1.78, P=0.040 and
HR=2.00, P=0.043, respectively]. In patients with de novo MBC, high EGF
expression was associated with a non-significant prolongation of TTP
(HR=0.52, P=0.080) and significantly longer survival (HR=0.40, P=0.020).
The present study examined clinical and biological implications of
specific genes and it was concluded that their expression has an impact
on the outcome of trastuzumab-treated patients with MBC.
ER -